Effects of hepatitis C-induced liver fibrosis on survival in kidney transplant candidates

Dig Dis Sci. 2007 Oct;52(10):2501-7. doi: 10.1007/s10620-006-9716-x. Epub 2007 Mar 30.

Abstract

We sought to investigate survival among kidney transplant candidates with varying degrees of liver fibrosis. We studied 108 patients with hepatitis C+ who underwent pre-kidney transplant liver biopsy (1992-2004). Eighteen patients had advanced fibrosis (bridging fibrosis or cirrhosis), and 90 had lesser degrees of fibrosis. Advanced fibrosis patients were younger and had lower prevalence of diabetes. Survival was similar between those with and without advanced fibrosis among all 108 patients (P = 0.92) and among the 58 patients who underwent kidney transplantation (P = 0.83). Fibrosis stage was associated with a 1.1 (0.72, 1.7; P = 0.65) adjusted hazards ratio for mortality among all 108 patients and a 0.64 (0.24, 1.73; P = 0.38) adjusted hazards ratio among the 58 patients who underwent kidney transplantation. These data support the premise that non-liver disease comorbidities are more important outcome determinants in this population. Kidney transplantation alone may be considered in patients with hepatitis C with compensated cirrhosis or bridging fibrosis.

MeSH terms

  • Adult
  • Antiviral Agents / therapeutic use
  • Biopsy
  • DNA, Viral / analysis
  • Female
  • Follow-Up Studies
  • Hepacivirus / genetics
  • Hepacivirus / immunology
  • Hepatitis C / complications*
  • Hepatitis C / drug therapy
  • Hepatitis C / pathology
  • Hepatitis C Antibodies / analysis
  • Humans
  • Immunoblotting
  • Kidney Failure, Chronic / surgery*
  • Kidney Transplantation / mortality*
  • Liver Cirrhosis / etiology*
  • Liver Cirrhosis / mortality
  • Liver Cirrhosis / pathology
  • Male
  • Middle Aged
  • Odds Ratio
  • Pennsylvania / epidemiology
  • Preoperative Care / methods*
  • Prognosis
  • Retrospective Studies
  • Reverse Transcriptase Polymerase Chain Reaction
  • Risk Factors
  • Severity of Illness Index
  • Survival Rate

Substances

  • Antiviral Agents
  • DNA, Viral
  • Hepatitis C Antibodies